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Determining the prevalence and type of antiretroviral (ARV) resistance among ARV-naïve individuals is im-
portant to assess the potential responses of these individuals to first-line regimens. The prevalence of primary 
resistance and the occurrence of recent infections among individuals with human immunodeficiency virus (HIV)/
acquired immune deficiency syndrome (AIDS) were identified among recently diagnosed patients at five sexually 
transmitted disease/AIDS testing and counselling centres in the metropolitan region of Recife (RMR), Pernambuco, 
Brazil, between 2007-2009. One-hundred and eight samples were analysed using the Calypte® BED assay. Males 
predominated (56%), as did patients aged 31-50 years. Twenty-three percent presented evidence of a recent HIV 
infection. The median CD4+ T lymphocyte count was 408 cells/mm3 and the median viral load was 3.683 copies/mL. 
The prevalence of primary resistance was 4.6% (confidence interval 95% = 1-8.2%) based on criteria that excluded 
common polymorphisms in accordance with the surveillance drug resistance mutation criteria. The prevalence of 
resistance to non-nucleoside reverse transcriptase, nucleoside/nucleotide reverse transcriptase and protease inhibi-
tors were 3.8%, 1.5% and 0.8%, respectively. Fifty-seven percent of strains were from clade B, 37.7% were clade F 
and 3.1% were clade C; there were no statistically significant differences with respect to resistance between clades. 
Recent infection tended to be more common in men (p = 0.06) and in municipalities in the south of the RMR (Ja-
boatão dos Guararapes and Cabo de Santo Agostinho) (p = 0.046). The high prevalence of recent infection and the 
high prevalence of non-B strains in this poor Brazilian region merit further attention.
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In Brazil, antiretroviral (ARV) therapy has been of-
fered universally and free of charge to human immuno-
deficiency virus (HIV)-positive individuals since 1997. 
Currently, approximately 200,000 people are undergo-
ing ARV treatment. The universal access to ARVs in 
Brazil has increased survival and improved the quality 
of life of patients with HIV/acquired immune deficiency 
syndrome (AIDS) (Teixeira et al. 2004). However, given 
the sequential use of ARVs in many Brazilian patients 
and the extensive use of non-boosted protease inhibi-
tors (PIs) in the recent past, it is assumed that a high 
proportion of patients experience virologic failure and 
develop ARV resistance, which can lead to the transmis-
sion of resistant strains. Initial infection with resistant 
strains can be related to virologic failure when treatment 
is started (Gagliani et al. 2011). The likelihood that a 
transmitted virus may be resistant to at least one ARV 
varies considerably. This variation is related primarily 
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to the differences in access to therapy (universal ver-
sus limited), risk behaviour, compliance with treatment 
(Paredes et al. 2010) and inclusion of volunteers exposed 
to ARVs, but not aware of or not willing to disclose this 
exposure. In USA and Europe, the prevalence of trans-
mitted ARV-resistant strains is between 5-18%; in Asia, 
this prevalence is 13.8% and in Africa it ranges from 2.2-
24% (Ceccherini-Silberstein et al. 2010). There are also 
regional variations in the prevalence of transmitted ARV 
resistance over time, with different studies demonstrat-
ing stability (Chaix et al. 2009), increases (Wheeler et 
al. 2010) or decreases in this prevalence (Bracciale et al. 
2009). Thus, local studies may play an important role in 
determining the prevalence of resistance among patients 
who have never previously taken ARVs, thereby avoiding 
the initial use of empirically ineffective ARVs and the use 
of more complex and more expensive ARV schemas than 
are needed to treat infected individuals in the region.
In Brazil, HIV/AIDS voluntary counselling and test-
ing (VCT) centres have been set up in the municipalities 
in which 70% of Brazilian AIDS cases are found. With the 
implementation of VCT centres in Brazil, access to HIV 
testing has increased and many asymptomatic, infected 
individuals have sought these centres at earlier stages of 
the disease to verify their HIV status (Grangeiro 2007).
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Investigating the molecular epidemiology of samples 
from HIV-seropositive individuals who have been diag-
nosed at VCT centres is of fundamental importance in 
understanding the details of each localised epidemic in a 
given region of Brazil. 
Recife is the capital of the state of Pernambuco (PE) 
in the Northeast Region of Brazil. This metropolitan re-
gion is an urban area with 3.6 million people (out of a to-
tal state population of 7.4 million). The Northeast Region 
of Brazil is considered less developed than the South-
east and South Regions of the country and the North-
east Region is experiencing an increasing prevalence of 
AIDS and higher AIDS-related mortality rates than are 
the southern Regions (MS 2010a). There are nine VCT 
centres located at strategic points throughout the metro-
politan region of Recife (RMR); these VCT centres are 
located at selected clinics where there is a high demand 
for HIV testing. The five VCT centres located in the 
most populous municipalities of the metropolitan region, 
namely Cabo de Santo Agostinho, Jaboatão dos Guara- 
rapes, Olinda, Paulista and Recife, account for the largest 
number of patients tested for HIV-1 in the RMR. Most of 
these centres have specialised outpatient clinics funded 
primarily by resources from the Department of Sexually 
Transmitted Disease (STD)/AIDS and Viral Hepatitis of 
the Brazilian Ministry of Health (MS 2010b).
In this study we sought (i) to determine the preva-
lence of primary resistance and recent infection among 
HIV-1-seropositive individuals who had been recently 
diagnosed at the five most important VCT centres in the 
RMR, (ii) to compare the characteristics of individuals 
with recent and established infections and (iii) to anal-
yse the socio-demographic characteristics of individuals 
with HIV-1 subtypes B and F.
SuBjeCtS, MAteriALS AnD MethODS
The users of the VCT centres selected for this study 
(Cabo de Santo Agostinho, Jaboatão dos Guararapes, 
Olinda, Paulista and Recife) were diagnosed as HIV 
positive by two different ELISA assays and one positive 
confirmatory test (immunofluorescence or western blot 
assay). When these individuals returned to the centres 
to receive their results, they were informed of this study 
during the post-test counselling. Those individuals who 
agreed to participate signed the informed consent docu-
ment and then blood was collected for HIV character-
ization and for the Calypte BED assay. Along with the 
specific form for the project, the samples were sent to 
the Virology Sector of Central Public Health Laboratory 
(LACEN)-PE and stored at -70ºC.
Between July 2007-March 2009, the partial HIV 
genomes from 130 samples from individuals who had 
recently been diagnosed with HIV-1 and had never re-
ceived ARV treatment were sequenced. 
Viral RNA was extracted using the QIAamp® RNA 
Mini Kit (Qiagen, Germany). For reverse transcription of 
the RNA to yield cDNA, polymerase chain reaction am-
plification followed by genetic sequencing of the product 
was performed using the TRUGENE® HIV-1 Genotyp-
ing Assay (Siemens Diagnostics, USA). This genotyping 
assay detects genomic HIV mutations in the protease 
(codons 1-99) and the reverse transcriptase (codons 10-
297) regions of the pol gene.
The genetic sequences generated were analysed us-
ing the OpenGene® DNA Sequencing System (Siemens 
Diagnostics, USA). ARV resistance mutations and sub-
types were submitted to the Stanford HIV Drug Resis-
tance Database (hivdb.stanford.edu) and the subtypes 
were further confirmed using SIMPLOT version 2. The 
mutations were identified in accordance with the surveil-
lance drug resistance mutation (SDRM) criteria, which 
exclude common polymorphisms in the evaluation of 
transmitted ARV-resistant HIV (Bennett et al. 2009). 
The Calypte® BED assay (Calypte Biomedical Corpora-
tion) was performed in accordance with the manufac-
turer’s instructions for the serological differentiation of 
recent seroconverters and long-term seroconverters.
The patients’ socio-demographic and laboratory data 
were retrieved from the sample referral records sent 
from the VCT centre to the Virology Sector of LACEN-
PE based on the user history provided by the Laboratory 
Test Result System database. The viral load and CD4+ 
T lymphocyte count were retrieved from Brazilian Sys-
tem of Laboratory Examinations Control. The Logistics 
Control System of Medicines (SICLOM), managed by 
the State Coordination of STD and AIDS of PE, was 
consulted to identify patients with prior exposure to 
ARVs among those patients whose viruses harboured 
resistance mutations.
Data were analysed using STATA version 9.0. De-
scriptive statistics are presented as percentages, medi-
ans and percentiles. The Kolmogorov-Smirnov test for 
normality was applied to the CD4 count and viral load 
data and the null hypothesis was rejected; thus, the non-
parametric Mann-Whitney test was used. We used the 
chi-squared test to compare proportions and we used 
Fisher’s exact test when necessary. Statistical signifi-
cance was set at the 5% level.
The study was approved by the Ethical in Research 
Committee of the Federal University of Pernambuco 
(protocol CEP/CCS/UFPE 120/07). 
reSuLtS
The patients’ characteristics are shown in Table I. 
Samples were available from 108 individuals for test-
ing for recent HIV infection and this testing revealed 
a prevalence of recent infection of 23.1% [confidence 
interval (CI) 95% 14.9-31.3%]. The prevalence of pri-
mary resistance was 6.1% (CI 95% 1.6-10.6%) based 
on International AIDS Society (IAS) (2008) (Johnson 
et al. 2008) table of mutations and 4.6% (CI 95% 1.0-
8.2%) based on the SDRM criteria (2009) (Bennett et 
al. 2009). Subtype B was the most prevalent (56.9%) in 
the study population, followed by F (37.7%), C (3.1%) 
and B/F (2.3%).
The mutations associated with resistance to reverse 
transcriptase inhibitors and PIs that were found among 
eight patients in the study are detailed in Table II, 
which also presents the socio-demographic and labora-
tory data of these patients.
The percentage of patients with recent infection var-
ied among the studied municipalities. The prevalence of 
recent infection was greater among patients from the city 
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TABLE I
Socio-demographic and laboratory characteristics of the samples sequenced  
from voluntary counselling and testing (VCT) volunteers
Characteristics Total
Individuals with primary 
resistance
IAS SDRM
Total [n(%)] 130 (100) 8 (6.1) 6 (4.6)
Age group [n (%)]
Under 30 years 57 (43.8) 5 (62.5) 5 (83.3)
31 years or over 73 (56.2) 3 (37.5) 1 (16.7)
Sex [n (%)]
Male 69 (53.1) 5 (62.5) 5 (83.3)
Female 61 (46.9) 3 (37.5) 1 (16.7)
VCT of origin [n (%)]
Recife 12 (9.2) - -
Olinda 9 (6.9) - -
Paulista 27 (20.8) 2 (25) 2 (33.3)
Jaboatão dos Guararapes 28 (21.5) 2 (25) 1 (16.7)
Cabo de Santo Agostinho 54 (41.5) 4 (50) 3 (50)
Exposure categorya [n (%)]
MSM 21 (16.2) 1 (50) 1 (50)
HTS/male 45 (34.6) 4 (50) 4 (50)
HTS/female 51 (39.2) 2 (66.7) 1 (33.3)
HIV+ partner 11 (8.5) 1 (100) -
Sex worker 2 (1.5) - -
HIV subtype [n (%)]
B 74 (56.9) 6 (75) 5 (83.3)
F 49 (37.7) 2 (25) 1 (16.7)
C 4 (3.1) - -
BF 3 (2.3) - -
Recent infectionb [n (%)]
Positive 25 (23.1) 1 (25) 2 (50)
Negative 83 (76.9) 3 (75) 2 (50)
CD4 (cells/mL)c
Median 408 470 428
Interquartile interval 195-693 332-544 256-635
Viral load (copies/ml)c
Median 3.683 17.671 53.259
Interquartile interval 208-24.224 4.095-67.776 20.947-179.220
a: the responses were not mutually exclusive; b: 22 samples were not tested (16.9%): of these, three patients had primary resistance 
according to International AIDS Society (IAS) and two patients according to surveillance drug resistance mutation (SDRM); c: 
for 34 patients, there was no information on the T CD4 lymphocyte count and viral load; HIV: human immunodeficiency virus; 
HTS: heterosexual; MSM: man who have sex with man.
of Recife and the southern region of the RMR (Jaboatão 
dos Guararapes and Cabo de Santo Agostinho), whereas 
the prevalence of chronic infection was greater among 
those patients from the northern region of the RMR 
(Olinda and Paulista). There was a trend towards a higher 
prevalence of recent infections among men (Table III).
There were no statistically significant differences 
with respect to socio-demographic and laboratory char-
acteristics between individuals with and without resis-
tance or between individuals infected by the B and F 
subtypes of HIV-1 (Table IV).
DiSCuSSiOn
The prevalence of primary resistance to ARVs (con-
sidering only reverse transcriptase inhibitors and PIs) 
observed in this study was 4.6% (CI 95% 1-8.2%) when 
using the SDRM criteria, which exclude common poly-
morphisms (Bennett et al. 2009). 
Due to the high cost of monitoring ARV resistance 
by means of genotyping, the World Health Organization 
recommends that the surveillance of resistance in small 
geographical areas should be stratified by applying a se-
quential sampling method known as threshold surveying 
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of HIV resistance, thus enabling the use of a small set of 
samples (n ≤ 50). This method classifies HIV resistance 
into three categories of prevalence: low (≤ 5%), moder-
ate (5-15%) and high (≥ 15%) (Myatt et al. 2008).
In Brazil, two major studies on the prevalence of 
primary HIV drug resistance were published in 2009. 
The first included 400 participants from 13 Brazilian 
cities. It is worth noting that only one centre, in Salva-
dor (in the Northeast Region), was located outside of 
the South and Southeast Regions and that 220 samples 
originated from the state of São Paulo (SP). Using the 
IAS criteria, the percentage of HIV-positive individu-
als whose viruses harboured resistance mutations was 
5.7% (Sprinz et al. 2009). In the present study, using 
samples from the RMR, the observed prevalence of 
resistance mutations was determined to be 6.1% when 
using the IAS criteria; this prevalence is very similar to 
that reported by Sprinz et al. (2009).
One evaluation carried out at a national level was the 
study of the National Network for the Surveillance of 
Drug Resistance in Brazil (HIV-BResNet), which results 
were published in 2009. This study included 210 recently 
diagnosed individuals from six state capitals in Brazil, 
of which two capitals were in the Southeast Region (São 
Paulo and Rio de Janeiro), one in the South Region (Porto 
Alegre), one in the Central-West Region (Brasília), one 
in the North Region (Belém) and one in the Northeast 
Region (Salvador). The individuals were classified ac-
cording to HIV mutations based on the SDRM criteria. 
In this study, 8.1% of the isolates harboured resistance 
mutations. The levels of resistance in São Paulo, Rio de 
Janeiro and Belém were intermediate (between 5-15%), 
whereas the levels were low (< 5%) in Brasília, Porto 
Alegre and Salvador (Inocêncio et al. 2009). 
Using the SDRM criteria, the present study showed 
that 4.6% of the strains had resistance mutations; this 
result coincides with the low resistance prevalence that 
has been detected outside of the Southeast Region, 
which is the epicenter of the HIV epidemic in Brazil 
(Inocêncio et al. 2009). These results are also similar to 
the results of a study conducted in Recife in 2002 that 
showed that 3.6% of HIV-positive patients were infect-
ed with viruses that harboured resistance-related muta-
tions (Medeiros et al. 2006).
Regarding the Northeast Region, data on the resist-
ance of HIV to drugs in the states of Bahia and Ceará 
(CE) have recently been published. The HIV BResNet 
study showed that there was a low rate of resistance to 
drugs - less than 5% - in Salvador (Inocêncio et al. 2009). 
A study conducted in CE found an intermediate rate of 
resistance, 9.5% (Arruda et al. 2010), which was higher 
than the rates of resistance found in the two major Bra-
zilian studies that included states outside of the South-
east Region. Given the differences in the data among 
these studies, in addition to the similarities among and 
the proximity of the three northeastern capitals, the pre-
cise composition of the populations in each study needs 
to be determined.
According to the analysis in the present study using 
the SDRM criteria, 3.84% of the mutations observed 
were associated with non-nucleoside reverse-tran-
scriptase inhibitors (NNRTIs), 1.53% with NRTIs and 
0.77% with PIs; this profile is similar to the profiles ob-
served recently in Brazil (Inocêncio et al. 2009, Sprinz 
et al. 2009) and elsewhere (Little et al. 2001).
From the analysis of the frequency of mutations asso-
ciated with each class of ARVs, we found that there were 
more mutations associated with NNRTIs, a finding that 
was absent from an earlier study carried out in Recife in 
2002 (Medeiros et al. 2006) and from a nationwide study 
(Brindeiro et al. 2003). 
Regarding NRTIs, unlike in other studies, in this 
study two of our samples contained viruses with the 184V 
mutation and only one sample contained a virus with the 
215F mutation. It is important to emphasize that the 184V 
mutation was found in the viruses of two individuals with 
recent infections, which may explain the presence of this 
mutation because there is a trend for this mutation to be-
TABLE II









Cabo-24913 F 25 Partner HIV+ B - 108Ia - - 480/1.093
Cabo-29524 M 27 MSM F - 103N - Negative -
Cabo-14149 M 26 HTS B 184V 101E, 190S - Positive -
Cabo-93 M 32 HTS B 184V, 215F, 219N 103N, 106I, 230L - Positive 566/470.000
Jaboatão-36720 F 45 HTS F - 108Ia - Negative 460/1.754
Jaboatão-37415 M 30 HTS B - - 46I, 73S, 
82A, 90M
Negative 842/82.294
Paulista-14785 M 47 HTS B - 190A - - 155/11.119
Paulista-16350 F 32 HTS B - 225H - - 290/24.224
a: mutation related to resistance only in the International AIDS Society classification; HIV: human immunodeficiency virus; 
HTS: heterosexual; MSM: man who have sex with man; NNRTI: non-nucleoside reverse-transcriptase inhibitor; NRTI: nucleo-
side reverse-transcriptase inhibitor; PI: protease inhibitor.
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come undetectable over time among individuals infected 
with ARV-resistant strains (Jain et al. 2011).
The present study revealed a high prevalence of recent 
infections (23%), but there were no significant differenc-
es in the prevalence of mutations between the recently 
and chronically infected populations (Fisher’s exact test, 
p = 0.327). Two samples from patients with recent infec-
tions and two samples from patients with chronic infec-
tions contained viruses that harboured NNRTI-related 
mutations, whereas NRTI-related mutations were found 
only in the viruses from the recently infected group (in 
2 samples). The only sample with a mutation related to 
a PI was found among the patients with chronic infec-
tions. These findings most likely reflect the greater cir-
culation of NNRTI-resistant strains, owing to the fact 
that NNRTIs are generally used in first-line regimens in 
Brazil (MS 2008). 
Recent infections tended to be more common in men, 
in the municipality of Recife and in the southern part of 
the RMR (Jaboatão dos Guararapes and Cabo de Santo 
TABLE III
Socio-demographic and laboratory data of HIV infected volunteers according to infection status
Characteristics Recent seroconverters Long-term seroconverters p
Total (n = 108) [n (%)] 25 (23.1) 83 (76.9) 0.000
Age group [n (%)]
Under 30 years 14 (56) 37 (44.6) 0.316
31 or over 11 (44) 46 (55.4) -
Sex [n (%)]
Male 18 (72) 42 (50.6) 0.060
Female 7 (28) 41 (49.4) -
VCT of origin [n (%)]
Recife 5 (20) 7 (8.4) 0.046
North part of RMR, Olinda, Paulista 3 (12) 29 (34.9) -
South part of RMR, Jaboatão dos Guararapes, 
Cabo de Santo Agostinho 17 (68) 47 (56.6) -
HIV subtype [n (%)]
B 15 (60) 44 (53) 0.600b
F 8 (32) 35 (42.2) -
Other 2 (8) 4 (4.8) -
Exposure categorya [n (%)]
MSM 7 (28) 11 (13.3) 0.161b
HTS 16 (64) 68 (81.9) -
HIV+ partner 2 (8) 4 (4.8) -
Primary resistance (IAS/SDRM) [n (%)]
Yes 2 (8) 3 (3.6) 0.327
No 23 (92) 80 (96.4) -
Main mutations [n (%)]
NRTI
Yes 2 (100) - Not performed
No - 3 (100) -
NNRTI
Yes 2 (100) 2 (66.7) Not performed
No - 1 (33.3) -
PI
Yes - 1 (33.3) Not performed
No 2 (100) 2 (66.7) -
CD4 (cells/mL)
Median (P25-P75) - - 0.275
c
Viral load (copies/mL)
Median (P25-P75) - - 0.498
c
a: the responses were not mutually exclusive; b: Fisher’s exact test; c: Mann-Whitney test; HIV: human immunodeficiency virus; 
HTS: heterosexual; IAS: International AIDS Society; MSM: man who have sex with man; NNRTI: non-nucleoside reverse-tran-
scriptase inhibitor; NRTI: nucleoside reverse-transcriptase inhibitor; PI: protease inhibitor; RMR: Recife metropolitan region; 
SDRM: surveillance drug resistance mutation; VCT: voluntary counselling and testing.
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TABLE IV
Characteristics of study population by human immunodeficiency virus (HIV)-1 subtypea and comparison  














Under 30 years 32 (43.2) 22 (44.9) 1 (25) 2 (66.7) 0.856
31-50 years 42 (56.8) 27 (55.1) 3 (75) 1 (33.3) -
Sex
Male 43 (58.1) 24 (49) 2 (50) 0 (0) 0.418
Female 31 (41.9) 25 (51) 2 (50) 3 (100) -
VCT of origin
Recife 9 (12.2) 3 (6.1) - - 0.469
North part of RMRb, Olinda, Paulista 20 (27) 12 (24.5) 2 (50) 2 (66.7) -
South part of RMRb, Jaboatão dos Guararapes, 
Cabo de Santo Agostinho 45 (60.8) 34 (69.4) 2 (50) 1 (33.3) -
Exposure category
MSM 12 (16.2) 9 (18.4) - - 0.948c
HTS 57 (77) 37 (75.5) 3 (75) 3 (100) -
HIV+ partner 5 (6.8) - 1 (25) - -
Primary resistance
IAS 6 (8.1) 2 (4.1) - - 0.607c
SDRM 5 (6.8) 1 (2) - - 0.446c
a: study by viral clades at pol region; b: comparison between subtypes B-F; c: Fisher’s exact test; HTS: heterosexual; IAS: In-
ternational AIDS Society; MSM: man who have sex with man; RMR: Recife metropolitan region; SDRM: surveillance drug 
resistance mutation; VCT: voluntary counselling and testing.
Agostinho). It should be noted that the severity of the 
AIDS epidemic continues to increase in the North-
east Region of Brazil. Recife currently ranks as the 
state capital with the fifth highest number of new 
cases of AIDS in Brazil, with a detection rate of 58.4 
cases/100,000 persons in 2010 (MS 2010a). Regarding 
the southern part of the RMR, the larger number of 
recent infections is most likely due to the presence of 
the tourist resort of Porto de Galinhas and the indus-
trial Port Complex of Suape, which is the new centre of 
economic development in the region. The availability of 
jobs at the resort and the port has resulted in the migra-
tion of young workers, some of them returning from the 
Southeast Region of Brazil (the epicenter of the AIDS 
epidemic in Brazil) back to their place of origin (IBGE, 
available from: ibge.gov.br/home/estatistica/populacao/
reflexoes_deslocamentos/ deslocamentos.pdf).
It should be noted that the patient sample included 
in the present study, which was exclusively recruited at 
VCT centres from among individuals recently diagnosed 
HIV, exhibited a prevalence of recent infection of 23%. 
The results for this sample may more accurately reflect 
the percentage of recent HIV infections in the general 
HIV-infected population in this region than the results 
for samples from studies conducted at hospitals that pro-
vide specialized care. We thus verified that over 75% of 
the infections had been present for more than six months, 
thereby increasing the likelihood of viral transmission. 
These results demonstrate the importance of more ac-
tions that are aimed at prevention and of easier access to 
HIV testing, particularly in the areas where the diagno-
sis was shown to have been made at a late stage, such as 
in the northern part of the RMR. However, a similar pro-
portion of recent HIV infections was found by Puchham-
mer-Stöckl et al. (2005) among newly diagnosed cases of 
HIV infection in Austria; this population is considered 
to be knowledgeable about HIV transmission and had 
easy access to diagnosis and widely available ARV treat-
ment. Another study that compared the immune status 
at presentation for HIV clinical care among two differ-
ent cohorts from Rio de Janeiro and Baltimore demon-
strated that more than 50% of the patients presented with 
CD4 counts < 350 cells/mm3 and 75% presented with 
viral loads > 10,000 copies/mm3 (Moreira et al. 2011). 
These findings reinforce the hypothesis that even in a 
population that is well informed about HIV, individual 
awareness of the risk of infection is still low.
As has been observed in all Regions of Brazil, ex-
cept the South, there is a predominance of HIV subtype 
B. However, in the present study, a high percentage of 
subtype F (37.7%) was detected in the RMR. This rate 
was much higher than that generally observed in other 
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regions of the country (Inocêncio et al. 2009). In addi-
tion, it appears that there may be a trend towards an in-
crease in the circulation of subtype F in this particular 
Region; the prevalence of this subtype was already high 
(26%) in Recife in 2002 according to a previous study 
(Medeiros et al. 2006). The prevalence of subtype F was 
22% in another study carried out between 2002-2004 us-
ing samples of patients with secondary resistance in PE 
(Cavalcanti et al. 2007). An epidemic of B/F recombinant 
strains that include circulating recombinants forms 28 
and 29 in approximately 50% of infected individuals 
was detected in the port city of Santos in the Southeast 
Region, where there are also high levels of transmitted 
resistance (Sucupira et al. 2007, Teixeira et al. 2010).
It is interesting to note that although subtype B is pre-
dominant in Brazil, there is a trend towards an increas-
ing prevalence of subtype C in the South and Southeast 
Regions of the country. In a recent study carried out in 
six Brazilian state capitals with ARV-naïve patients, 
Inocêncio et al. (2009) observed a rate of 69% of subtype 
C in Rio Grande do Sul; this rate is much higher than 
that found by Brígido et al. (2007). In addition, Brígido 
et al. (2011) discovered an increased presence of subtype 
C in SP. It is of note that resistance-related mutations 
may vary among different subtypes in Brazil (Munerato 
et al. 2010) and studies targeting non-B strains certainly 
merit further attention.
We recognize that the small number of samples and 
the small size of the genomic region of HIV character-
ized in this study may preclude more definitive conclu-
sions. In addition, a further limitation was the sampling 
bias; a smaller number of samples from Recife was ana-
lyzed despite its being the largest city in the region. This 
sampling bias precluded making more comparisons be-
tween the isolates. However, we found that there is an 
increased prevalence of subtype F in this region. 
Transmitted resistance is still low, but the profile of 
transmitted mutations may be changing in this region. Fu-
ture trends need to be carefully observed and evaluated.
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